bioAffinity Technologies/$BIAF
14:30
15:25
16:15
17:10
18:00
1D1W1MYTD1Y5YMAX
About bioAffinity Technologies
bioAffinity Technologies Inc addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and targeted cancer treatment. It develops proprietary noninvasive diagnostic tests and cancer therapeutics using technology that preferentially targets cancer cells and cell populations indicative of a diseased state. The company's product, CyPath Lung, is a noninvasive test for the detection of early-stage lung cancer.
Ticker
$BIAF
Sector
Primary listing
Employees
57
Headquarters
Website
BIAF Metrics
BasicAdvanced
$6.7M
-
-$20.28
2.33
-
Price and volume
Market cap
$6.7M
Beta
2.33
52-week high
$7.29
52-week low
$1.25
Average daily volume
173K
Financial strength
Current ratio
3.65
Quick ratio
3.441
Long term debt to equity
3.197
Total debt to equity
7.649
Interest coverage (TTM)
-184.25%
Profitability
EBITDA (TTM)
-9.847
Gross margin (TTM)
27.86%
Net profit margin (TTM)
-217.50%
Operating margin (TTM)
-153.20%
Effective tax rate (TTM)
-0.28%
Revenue per employee (TTM)
$120,000
Management effectiveness
Return on assets (TTM)
-71.71%
Return on equity (TTM)
-245.18%
Valuation
Price to revenue (TTM)
0.161
Price to book
0.58
Price to tangible book (TTM)
0.77
Price to free cash flow (TTM)
-0.128
Free cash flow yield (TTM)
-780.34%
Free cash flow per share (TTM)
-11.705
Growth
Revenue change (TTM)
-27.66%
Earnings per share change (TTM)
-13.89%
3-year revenue growth (CAGR)
1,302.40%
3-year earnings per share growth (CAGR)
-44.40%
BIAF News
AllArticlesVideos
bioAffinity Technologies Reports Third Quarter 2025 Financial Results
Business Wire2 weeks ago
bioAffinity Technologies Presents Research Supporting CyPath® Lung Processing Methods at CHEST 2025
Business Wire1 month ago
bioAffinity Technologies, Inc. Announces Closing of $1.8 Million Registered Direct Financing of Common Stock Priced At-The-Market Under Nasdaq Rules
Business Wire2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for bioAffinity Technologies stock?
bioAffinity Technologies (BIAF) has a market cap of $6.7M as of December 01, 2025.
What is the P/E ratio for bioAffinity Technologies stock?
The price to earnings (P/E) ratio for bioAffinity Technologies (BIAF) stock is 0 as of December 01, 2025.
Does bioAffinity Technologies stock pay dividends?
No, bioAffinity Technologies (BIAF) stock does not pay dividends to its shareholders as of December 01, 2025.
When is the next bioAffinity Technologies dividend payment date?
bioAffinity Technologies (BIAF) stock does not pay dividends to its shareholders.
What is the beta indicator for bioAffinity Technologies?
bioAffinity Technologies (BIAF) has a beta rating of 2.33. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.